Evidence map›Paper›PMID 33191319›Full record

ArticleInternal medicine (Tokyo, Japan)2021

Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.

Kaname Miyashita, Yui Hongo, Akihiko Nakashima, Seiya Kato, Hironori Kusano, Shusuke Morizono, Nobuhiko Higashi

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kaname MiyashitaDepartment of Haematology, Saiseikai Fukuoka General Hospital, Japan.
Yui HongoDepartment of Diabetes and Endocrinology, Saiseikai Fukuoka General Hospital, Japan.
Akihiko NakashimaDivision of Pathology, Saiseikai Fukuoka General Hospital, Japan.
Seiya KatoDivision of Pathology, Saiseikai Fukuoka General Hospital, Japan.
Hironori KusanoDepartment of Pathology, Kurume University School of Medicine, Japan.
Shusuke MorizonoDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Japan.
Nobuhiko HigashiDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Japan.
Saiseikai Fukuoka General Hospital · JPKyushu University · JPKurume University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 79-year-old man with lymphoma who tested negative for anti-hepatitis C virus (HCV) antibody received rituximab-containing chemotherapy. Liver dysfunction of unknown cause had persisted since the second cycle of chemotherapy. Ten months after treatment, he rapidly developed massive ascites and atrophy of the liver, and we detected HCV RNA in his serum using real time polymerase chain reaction. Furthermore, medical interviews showed that the patient had no episodes for acute HCV infection, but he did have a history of unspecified liver dysfunction. These findings support the possibility of the reactivation of seronegative occult HCV infection due to chemotherapy in a cancer patient.

Indexed as

Hepatitis CLymphomaAgedHepacivirusHepatitis B Surface AntigensHepatitis B virusHumansMaleRituximabVirus ActivationHepatitis B Surface AntigensRituximabchemotherapyhepatitis C virus reactivationmalignant lymphomaoccult hepatitis C virus infectionR-CHOP therapy

Identifiers

PMID33191319
PMCPMC8188017
OpenAlexW3105619296

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.